Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6274668 | 0.98 | ALDH1A1 (0.62) | ALDH1A1CYP1A2KMT2APOLBMAPT | |
| Hydrochloric Acid SCHEMBL27319280 | 0.98 | ALDH1A1 (0.62) | ALDH1A1CYP1A2KMT2APOLBMAPT | |
| SCHEMBL1566720 | 0.98 | ALDH1A1 (0.62) | ALDH1A1CYP1A2KMT2APOLBMAPT | |
| Fluoromethane SCHEMBL27359815 | 0.94 | ALDH1A1 (0.58) | ALDH1A1CYP1A2KMT2APOLBMAPT | |
| Acetic Acid SCHEMBL27316996 | 0.94 | ALDH1A1 (0.58) | ALDH1A1CYP1A2KMT2APOLBMAPT | |
| SCHEMBL27480275 | 0.91 | ALDH1A1 (0.55) | ALDH1A1CYP1A2KMT2APOLBMAPT | |
| SCHEMBL27334382 | 0.91 | ALDH1A1 (0.55) | ALDH1A1CYP1A2KMT2APOLBMAPT | |
| SCHEMBL9701780 | 0.90 | ALDH1A1 (0.58) | ALDH1A1CYP1A2KMT2APOLBMAPT | |
| SCHEMBL6687953 | 0.89 | ALDH1A1 (0.54) | ALDH1A1CYP1A2KMT2APOLBMAPT | |
| SCHEMBL27814364 | 0.89 | ALDH1A1 (0.53) | ALDH1A1CYP1A2KMT2APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577202-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-07-02 | — | — | EP | claimed |
| CN-119923254-A | Use of therapeutic agents having sodium hydrogen antiport 1 inhibitory activity for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or fatigue intolerance | 米托迪治愈有限责任公司 | 2025-05-02 | — | — | CN | claimed |
| WO-2024042160-A1 | USE OF A THERAPEUTIC AGENT WITH SODIUM-HYDROGEN ANTIPORTER 1 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-29 | — | — | WO | claimed |
| CN-115317474-A | Application of benzoylguanidine derivative in preparation of medicine for preventing and treating nervous system diseases or cardiovascular system diseases | 中国海洋大学 | 2022-11-11 | — | — | CN | claimed |
| US-10472332-B2 | Antiviral compounds and methods | BIOTRON LIMITED (AU) | 2019-11-12 | — | — | US | claimed |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2017-09-14 | — | — | US | claimed |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | BIOTRON LIMITED (AU) | 2015-11-05 | — | — | US | claimed |
| CN-104447623-A | Compound capable of protecting myocardium from ischemia reperfusion injury and application of compound | UNIV PLA 2ND MILITARY MEDICAL | 2015-03-25 | — | — | CN | claimed |
| US-20130217707-A1 | TREATING ATTENTION DEFICIT HYPERACTIVITY DISORDER WITH NHE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2013-08-22 | — | — | US | claimed |
| EP-2617709-A1 | Guanidine derivatives as antiviral agents | Biotron Limited (AU) | 2013-07-24 | — | — | EP | claimed |
| EP-0589336-A1 | Benzoylguanidines, process for their preparation and their use as antiarrhythmic agents | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-30 | — | — | EP | claimed |
| US-5292755-A | USPA benzolyguanidines | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-03-08 | — | — | US | claimed |
| EP-0577024-A1 | 3,4,5 substituted benzoylguanidines, process for their preparation, their use as medicament or diagnostic agent, as well as a medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-01-05 | — | — | EP | claimed |
| CN-1075960-A | Amino benzoyl guanidine, its preparation method that replaces is as the purposes and the medicament that contains it of medicine | HOECHST AG (DE) | 1993-09-08 | — | — | CN | claimed |
| EP-0556673-A1 | Ortho-substituted benzoylguanidines for the treatment and prophylaxis of heart-rhythm disorders and ischaemically induced damage, as well as inhibition of cell proliferation | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | claimed |
| EP-0556672-A1 | Amino-substituted benzoylguanidines with antiarrhythmic properties | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | claimed |
| EP-0556674-A1 | 3,5-substituted benzoylguanidines with antiarrhythmic activity and cell proliferation inhibiting activity | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-08-25 | — | — | EP | claimed |
| US-5091394-A | BENZOYLGUANIDINES, A PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICAMENTS AND MEDICAMENTS CONTAINING THEM | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | claimed |
| CN-1050018-A | Benzoylguanidines, they the preparation method, they are as the application of medicament and the medicament that contains them | HOECHST AG (DE) | 1991-03-20 | — | — | CN | claimed |
| EP-0416499-A2 | Benzoylguanidines, process for their preparation, their use as medicaments as well as medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-03-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10472332-B2 | Antiviral compounds and methods | MAVS, ZC3HAV1, EIF2AK2 | ALDH1A1 2843/4885CYP1A2 3645/4885KMT2A 2454/4885 |
| US-20170260147-A1 | ANTIVIRAL COMPOUNDS AND METHODS | MAVS, ZC3HAV1, EIF2AK2 | ALDH1A1 2843/4885CYP1A2 3645/4885KMT2A 2454/4885 |
| US-20150313909-A1 | ANTIVIRAL COMPOUNDS AND METHODS | ZC3HAV1, MAVS, EIF2AK2 | ALDH1A1 3132/4885CYP1A2 3795/4885KMT2A 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.